Current possibilities and problems of antiretroviral therapy

Česká verzia

Authors: L. Machala; D. Jilich
Authors place of work: Primářka: MUDr. Hana Roháčová, Ph. D. ; AIDS centrum, Infekční klinika FN Bulovka, Praha
Published in the journal: Prakt. Lék. 2008; 88(2): 71-77
Category: Reviews

Summary

The introduction of antiretroviral therapy to clinical practice has assured a significant improvement in the quality of life for people living with HIV infection, and has substantially prolonged their life expectancy. At present there are four classes of antiviral drugs in clinical use and several new promising molecules are in various stages of clinical research and development. The major problems with current antiretroviral therapy are the occurrence of serious side-effects and a relatively quick development of resistance. Good cooperation between the patient and the physician is essential for the success of antiretroviral therapy. This success is based primarily on careful monitoring of side-effects by the physician and maximum adherence by the patient. The new antiretroviral drugs under development are thus expected to have lower toxicity and lower sensitivity to the development of viral resistance. The new drugs should be also cheaper because, due to the high costs of the antiretroviral drugs that are currently being used, only about 25 % of all people indicated for treatment worldwide have access to therapy.

Key words:
HIV, AIDS, therapy, resistance, side-effects.

Zdroje

1. Mitsuya, H., Weinhold, K., Furman, P. et al. 3‘-Azido-3‘-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 1985, 82, p. 7096-7100.

2. Brook. I. Approval of zidovudine (AZT) for acquired immunodeficiency syndrome. A challenge to the medical and pharmaceutical communities. JAMA 1987, 258, p. 1517.

3. Walensky, R., Paltiel, A., Losina, E. et al. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 2006, 194, p. 11-19.

4. WHO/UN AIDS: Progress in scaling up access to HIV treatment in low and middle-income countries, June 2006. Fact Sheet. Geneva 2006.

5. James, J. Tenofovir approved: broad indication. AIDS Treat. News 2001. (373), p. 2-3.

6. James, J. Saquinavir (Invirase): first protease inhibitor approved - reimbursement, information hotline numbers. AIDS Treat. News 1995 (237), p. 1-2.

7. Bowerson, J. Nevirapine approved by FDA. Food and Drug Administration. NIAID AIDS Agenda 1996, 10.

8. Robertson, D. US FDA approves new class of HIV therapeutics. Nat. Biotechnol. 2003, 21, p. 470-471.

9. Laurence, J. Immune restoration and HAART: new clinical and in vitro data. AIDS Read. 2002, 12, p. 421-422.

10. Lange, C., Lederman, M., Madero, J. et al. Impact of supression of viral replication by highly active antiretroviral therapy on immune functions and phenotype in chronic HIV-1 infection. J. Acquir. Immune. Defic. Syndr. 2002, 30, p. 33-40.

11. Bartlett, J., Gallant, J. Medical management of HIV infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group, 2004.

12. Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1 Infected women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Dostupné na http://aidsinfo.nih.gov/guidelines, 2005.

13. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR 2005, 54, (No. RR-2).

14. Health Protection Agency Centre for Infections & Collaborators: Occupational transmission of HIV. Summary of published Reports. March 2005 Edition. Dostupné na http://www.hpa.org.uk.

15. Almeda, J., Casabona, J., Simon, B. et al. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill. 2004, 9, p. 35-40.

16. Puro, V., Cicalini, S., De Carli, G. et al. Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur. J. Epidemiol. 2004, 19, p. 577-584.

17. Blankson, J. Primary HIV-1 infection: to treat or not to treat? AIDS Read. 2005, 15, p. 245-251.

18. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-1 infected adults and adolescents. MMWR Recommend Rep. 2002; 51(RR-7).

19. Bartlett, J., Gallant, J. Medical management of HIV Infection - 2005-2006 Edition. Baltimore: John Hopkins Medicine Health Publishing Business Group, 2005.

20. Mocroft, A., Phillips, A., Soriano, V. et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res. Hum. Retroviruses 2005, 21, p. 743-752.

21. Schiller, D. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am. J. Health-Syst. Pharm. 2004, 61, p. 2507-2522.

22. Hofman, P., Nelson, A. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr. Med. Chem. 2006, 13, p. 3121-3123.

23. Ogedegbe, A., Sulkowski, M. Antiretroviral-associated liver injury. Clin. Liver Dis. 2003, 7, p. 475-499.

24. Bourezane, Y., Salard, D., Hoen, B. et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin. Infect. Dis. 1998, 27, p. 1321-1322.

25. Hawkins, T. Appearence-related side effects of HIV-1 treatment. AIDS Patient Care STDS 2006, 20, p. 6-18.

26. Rustin, P. Mitochondrial dysfunction in HIV infection: an overview of pathogenesis. J. HIV Ther. 2001, 6, p. 4-12.

27. Simpson, D., Estanislao, L., Evans, S. et al. HIV-associated neuromuscular weakness syndrome. AIDS 2004, 18, p. 1403-1412.

28. Carr, A., Samaras, K., Burton, S. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12, F51-F58.

29. Snopková, S., Husa, P. Metabolický syndrom u onemocnění HIV/AIDS. Klin. mikrobiol. inf. lék. 2006, 12, s. 108-116.

30. Carr, A., Samaras, K., Thorisdottir, A. et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353, p. 2093-2099.

31. Yan, Q., Hruz, P. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J. Acquir. Immune. Defic. Syndr. 2005, 40, p. 398-403.

32. d‘Arminio Monforte, A., Sabin, C., Phillips, A. et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004, 18, p. 1811-1817.

33. Richman, D., Fischl, M., Grieco, M. et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, p. 192-197.

34. Mary-Krause, M., Billaud, E., Poizot-Martin, I. et al. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS 2006, 20, p. 1627-1635.

35. Walsh, K., Kave, K., Demaerschalk, B. et al. AZT myopathy and HIV-1 polymyositis: one disease or two? Can. J. Neurol. Sci. 2002, 29, p. 393-393.

36. De Ponti, A. Adhesive capsulitis of the shoulder in human immunodeficiency virus-positive patients during highly active antiretroviral therapy. J. Shoulder Elbow Surg. 2006, 15, p. 188-190.

37. de Maat, M., ter Heine, R., Mulder, J. et al. Incidence and risk factors for nevirapine-associated rash. Eur. J. Clin. Pharmacol. 2003, 59, p. 457-462.

38. Trottier, B., Walmsley, S., Reynes, J. et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune. Defic. Syndr. 2005, 40, p. 413-421.

39. Phillips, E., Wong, G., Kaul, R. et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005, 19, p. 979-981.

40. Gallego, L., Barreiro, P., del Rio, R. et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin. Infect. Dis. 2004, 38, p. 430-432.

41. Brew, B. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 2003, 28, p. 542-552.

42. Gallant ,J., Parish, M., Keruly, J. et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 2005, 40, p. 1194-1198.

43. Jevtovic, D., Salemovic, D., Ranin ,J. et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005, 6, p. 140-143.

44. Murphy, D., Marelich, W., Hoffman, D. et al. Predictors of antiretroviral resistance. AIDS Care 2004, 16, p. 471-484.

45. UNAIDS: International Guidelines on HIV/AIDS and Human Rights. Geneva, 2006.